Search results
Results from the WOW.Com Content Network
Practicing physicians have dismissed the concept of mucoid plaque as a hoax and a "non-credible concept". [4] A pathologist at the University of Texas School of Medicine addressed Anderson's claims directly, saying that he has "seen several thousand intestinal biopsies and have never seen any 'mucoid plaque.' This is a complete fabrication with ...
A mucinous neoplasm (also called colloid neoplasm) is an abnormal and excessive growth of tissue with associated mucin (a fluid that sometimes resembles thyroid colloid).
Download as PDF; Printable version; In other projects ... FOLFOXIRI is a chemotherapy regimen for the treatment of advanced colorectal cancer. [1 ... The role of ...
A type of bacteria that causes dental plaque may be behind a treatment-resistant form of colorectal cancer, a study published Wednesday in the journal Nature found.. The particular bacterium ...
Another use is in surgical pathology where it can identify mucin. This is helpful, for example, in determining if the cancer is a type that produces mucin. Example would be to distinguish between high grade Mucoepidermoid Carcinoma of the parotid, which stains positive vs Squamous Cell Carcinoma of the parotid which does not.
Success of the preoperative regimen changed the paradigm of anal cancer treatment from surgical to non-surgical and was the advent of definitive chemoradiation (omitting surgery) being accepted as a standard-of-care for anal squamous cell carcinomas. Larger doses of radiation are used in modern chemoradiotherapy protocols versus the original ...
Pseudomyxoma peritonei (PMP) is a clinical condition caused by cancerous cells (mucinous adenocarcinoma) that produce abundant mucin or gelatinous ascites. [1] The tumors cause fibrosis of tissues and impede digestion or organ function, and if left untreated, the tumors and mucin they produce will fill the abdominal cavity.
Adjuvant treatment in patients with stage III colon cancer is recommended [2] for 12 cycles, every two weeks. The recommended dose schedule is as follows: Day 1: Oxaliplatin 85 mg/m 2 intravenous (IV) infusion in 250-500 mL D5W and leucovorin 200 mg/m 2 IV infusion in D5W administered concurrently over 120 minutes in separate bags using a Y-line, followed by fluorouracil (5-FU) 400 mg/m 2 IV ...